Drug Patent Expirations in April 2013

Drug Patent Expirations for April 2013

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
BROVANA
Sunovion
arformoterol tartrate
6,589,508
Apr 3, 2013

RAPLON
Organon Usa Inc
rapacuronium bromide
5,418,226
Apr 14, 2013

ACUTECT
Cis Bio …




Click here for reuse options!
Copyright 2013 Biotechblog

Will the UK be the Goose that Lays The Golden Access?

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. This month sees the introduction of the UK’s Open Access policy as recommended by the government-commissioned Finch Report into […]




Click here for reuse options!
Copyright 2013 Biotechblog

Taking stock in biotechnology futures

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Taking stock in biotechnology futures
Go to paperABSTRACT: Investors now have a new tool to help them manage the risk associated with biotechnology investm…




Click here for reuse options!
Copyright 2013 Biotechblog

Drug Patent Expirations for Mar 12 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for March 12 2013

Tradename Applicant Generic Name Patent
Expiration
ABRAXANE Abraxis Bioscience paclitaxel Mar 12, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium
bromide
Mar 12,
2013

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Which pharmaceutical companies listed the most drug patents last
year

Which Companies Listed the Most Drug
Patents Last Year?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.






Click here for reuse options!
Copyright 2013 Biotechblog

New Journal of Commercial Biotechnology issue

Journal of Commercial Biotechnology Vol 19, Issue 2 (2013) Capturing Value G. Steven Burrill Today’s pressure on pharmaceutical companies reflects greater pressures throughout the entire healthcare ecosystem as payers, patients, and providers wrestle with escalating costs and drive  healthcare systems around the world away from being cost-based to becoming value-based.  For pharmaceutical companies, this means […]




Click here for reuse options!
Copyright 2013 Biotechblog

Should the HHS Decision to Overrule FDA on Plan B Be Reversed

On December 7, 2011, Secretary of Health and Human Services Kathleen Sebelius overruled a decision of the Food and Drug Administration (FDA) on the over-the-counter (OTC) status of emergency contraception.

What will be the repercussions of Secretary Sebelius’s action? Why is the act itself of far greater long-term significance than the transitory regulatory action it impacts?

By reversing an FDA decision, the Secretary has set a dangerous precedent for all-comers to lobby Congress, the Department of Health and Human Services (HHS) and the White House on any and all FDA decisions—directly inserting politics into what must be a scientifically driven process.

Full details at the Journal of Commercial Biotechnology




Click here for reuse options!
Copyright 2013 Biotechblog

A Patient Centric Commercial Model for Cancer Care

Cancer is one of the most challenging diseases of all – not only in terms of the clinical barriers to offering its sufferers respite from devastating consequences, but also to manufacturers and marketers of treatments that attempt to control its impact…




Click here for reuse options!
Copyright 2013 Biotechblog

Getting Social with Biotechnology Business Development

Social media is becoming increasingly important in business. While the lack of regulations makes marketing online to consumers a challenge in the life sciences, social media offers significant opportunities to the industry by complementing traditional business development and capital raising activities.

 

With relatively little effort and expense, companies can build networks, gain trust, and obtain introductions with previously inaccessible targets and distant markets. In embracing social media, individuals themselves become more approachable and open themselves up to business growth that might otherwise have been unattainable.

Full details at the Journal of Commercial Biotechnology




Click here for reuse options!
Copyright 2013 Biotechblog

The financial ecosystem available to early-stage biotechnology firms and its misalignment with interests of these firms, of the biotechnology industry and with global disease burden

The development and commercialization of new therapeutics have had immense impact on the quality and length of human life.  Nevertheless, the biotechnology and the pharmaceutical industry have evolved to be driven mostly by a profit oriented market system, in which distinct stakeholders interact with different motivations to make the development and commercialization of therapeutics a reality.  This study discusses the funding ecosystem available for early-stage biotechnology companies and its influence on the their strategic business objectives and on the biotechnology industry.  On the basis of this, distinct paradoxes in the funding ecosystem are uncovered, which suggest that the present ecosystem is not well aligned with the interests of these biotechnology firms, the biotechnology industry, and it neglects strategic disease burden needs. It is recommended that even partial resolution of these paradoxes will enable further growth in the industry and lead to more innovative therapies for untreatable diseases with large social and economic burdens.  In light of this, the study proposes improvements of financing approaches and an increase of available capital in the funding ecosystem of early-state biotechnology companies.

Full details at the Journal of Commercial Biotechnology




Click here for reuse options!
Copyright 2013 Biotechblog

Challenges and prospects for monoclonal antibodies in China

The technology of monoclonal antibodies has been developed since the 1990s and is attracting more and more attention in China during the 21st century. The first monoclonal antibody product was introduced by the Chinese local producer in 1999, and presently seven products are listed, of which three are humanized products. There are several technical constraints that are affecting the development of monoclonal antibodies in China: limitations to the number of drug targets, restricted biological diffusion, limitations to administration routes, and species-specific issues, as well as China’s own limitations in production and R&D capabilities. This article provides suggestions relevant for the Chinese development of monoclonal antibodies. In the long run China is expected to catch up with its own technology roadmap.

Full details at the Journal of Commercial Biotechnology




Click here for reuse options!
Copyright 2013 Biotechblog

%d bloggers like this: